Senesco Technologies, Inc.'s Drug Candidate SNS01-T Selectively Kills Cancer Cells And Not Healthy Cells In Disease Models
Published: Dec 10, 2013
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB: SNTI) reported results of preclinical studies with SNS01-T at the 55th American Society of Hematology Annual Meeting in New Orleans.
Help employers find you! Check out all the jobs and post your resume.